Industry News

ACR Takes Steps to Close the Gap in Lupus Care

October 30, 2020

The American College of Rheumatology has launched a project designed to resolve inequities in care for patients with systemic lupus erythematosus, a condition that is two or three times more common among ethnic minorities. In this interview, S. Sam Lim, M.D., MPH, chair of ACR’s Collaborative Initiatives Special Committee, tells us more about the project.

Dapagliflozin Earns Breakthrough Therapy Designation for Chronic Kidney Disease

October 02, 2020

Dapagliflozin (Farxiga, AstraZeneca) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration for patients with chronic kidney disease with and without type 2 diabetes. It is currently approved as a treatment to improve glycemic control in adults with type 2 diabetes.

Tofacitinib Approved for Juvenile Arthritis

September 30, 2020

The U.S. Food and Drug Administration has approved tofacitinib Xeljanz, Pfizer) for the treatment of children and adolescents two years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA).

New Treatment Approved for Devic’s Disease

August 18, 2020

The U.S. FDA has approved a third treatment for the rare autoimmune condition, Devic's disease. The condition is associated with blindness and paralysis and often coexists with other rheumatic conditions, such as lupus and rheumatoid arthritis.

New RA Biosimilar Approved for U.S. Market

July 14, 2020

The U.S. FDA has approved the sixth biosimilar to Humira, adalimumab-FKJP (Hulio), which will be available in the United States in 2023 for rheumatoid arthritis, psoriatic arthritis, psoriasis, juvenile arthritis and other conditions.

Guselkumab Approved for Psoriatic Arthritis

July 14, 2020

The U.S. Food and Drug Administration has approved the first IL-23 inhibitor for moderate to severe psoriatic arthritis. The newly approved treatment, guselkumab, has been shown to improve the signs and symptoms of fatigue associated with PsA.

Secukinumab Approved for Active Non-radiographic Axial Spondyloarthritis

June 19, 2020

Secukinumab, an IL-17a inhibitor currently approved in the United States for moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis, has been approved by the U.S. Food and Drug Administration for the treatment of active non-radiographic axial spondyloarthritis.